Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ironwood Pharmaceuticals nets $191mm in FOPO

Executive Summary

Ironwood Pharmaceuticals Inc. (therapeutics targeting guanylate cyclase) netted $191mm in a follow-on public offering of 15.8mm Class A common shares (including the overallotment) for $12.75. Proceeds will support continued US marketing of Linzess (linaclotide), launched in December 2012 for IBS with constipation and chronic idiopathic constipation, and co-promoted with Forest under a 2007 deal. Thanks to a recent notice of allowance from the US Patent and Trademark Office on a Linzess patent application, the drug could now have patent protection through 2031. Ironwood will also apply the money to further develop linaclotide (in new indications, formulations, and in combination with other products) and GI drug candidates.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies